Following funding from the DoD, the UK-based Euprotec is collaborating with Mauritius-based Fulhold and the New Jersey Medical School-UMDNJ to assess a topical broad spectrum antimicrobial agent for use in US soldiers’ battle-packs.
The Fulhold’s CHD-FA is considered to be suitable for use in soldiers’ battle-packs or in the first aid situations as it is safe and stable at high temperatures.
Euprotec CEO Dr Lloyd Payne said, "It is critical that we address antimicrobial resistance and CHD-FA offers significant potential for the prevention of serious wound infections."
CHD-FA also demonstrates potent broad spectrum antimicrobialactivity against a large range of multidrug resistant Gram positive and Gram negative bacteria such as MRSA, NDM-1 positive E. coli, carbapenem-resistant Enterobacteriaceae (CRE), tuberculosis and pathogenic fungi.
Fulhold director Wally Strickland said, "We have believed in the potential of CHD-FA to treat drug resistant wound infections for many years and have completed a number of research projects with Euprotec."